drugset / Trial / NCT00383422

Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis

NCT00383422

Phase 3 Completed 320 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the effect of arzoxifene to raloxifene on the bone mineral density (bone strength).

Timeline

Start
2006-10
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Raloxifene Other / unclassified 60 mg Oral
Subject arzoxifene Other / unclassified 20 mg Oral